|
注册号: Registration number: |
ChiCTR2000039425 |
|
最近更新日期: Date of Last Refreshed on: |
2023-10-16 16:47:08 |
|
注册时间: Date of Registration: |
2020-10-27 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
重症监护病房获得性衰弱高风险患者综合活动分级护理路径的建立 |
|
Public title: |
Establishment of comprehensive activity grading nursing pathway for high risk patients with intensive care unit acquired weakness |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
重症监护病房获得性衰弱高风险患者综合活动分级护理路径的建立 |
|
Scientific title: |
Establishment of comprehensive activity grading nursing pathway for high risk patients with intensive care unit acquired weakness |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李冰 |
研究负责人: |
李冰 |
|
Applicant: |
Li Bing |
Study leader: |
Li Bing |
|
申请注册联系人电话: Applicant telephone: |
+86 136 7128 4086 |
研究负责人电话:
Study leader's |
+86 136 7128 4086 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
crystallibing@126.com |
研究负责人电子邮件: Study leader's E-mail: |
crystallibing@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
28 Fuxing Road, Haidian District, Beijing |
Study leader's address: |
28 Fuxing Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院 |
||
|
Applicant's institution: |
Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院 |
||
|
Affiliation of the Leader: |
Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审第S2021-643-02号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-05-31 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Cao Jiang |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
28 Fuxing Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
301irb@sina.com |
|
研究实施负责(组长)单位: |
中国人民解放军总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
北京市科技委员会 |
||||||||||||||||||||||
|
Source(s) of funding: |
Beijing Municipal Commission of science and technology |
||||||||||||||||||||||
|
研究疾病: |
ICU获得性衰弱 |
||||||||||||||||||||||
|
Target disease: |
ICU-acquire weakness |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
建立 ICU-AW 高风险患者综合活动分级护理路径并进行临床验证,指导临床科学规范的实施危重症患者的早期功能锻炼,为制定相关行业规范提供依据,有望通过课题实施和推广为降低 ICU 获得性衰弱发生率,提高危重症患者救治效果 提供科技支撑。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study is to establish ICU-AW high-risk patients comprehensive activity grading nursing pathway and carry out clinical verification, guide the implementation of clinical scientific norms of early functional exercise of critically ill patients, provide the basis for the formulation of relevant industry norms, and is expected to provide scientific and technological support for reducing the incidence of ICU-AW acquired weakness and improving the treatment effect of critically ill patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
通过证据总结、专家论证、现场调查等方法,建立适用于监护病房的获得性衰弱高风险患者的活动内容明确、操作性强的综合活动护理路径。采用这一路径作为干预措施,严重临床应用效果。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Through the methods of evidence summary, expert argumentation and field investigation, a comprehensive activity nursing path suitable for ICU patients with high risk of acquired weakness was established. Using this pathway as an intervention measure, serious clinical application effect. |
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
排除存在下列情况的患者: |
||||||||||||||||||||||
|
Exclusion criteria: |
Patients with the following conditions were excluded: |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-06-01 00:00:00至 To 2025-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-01 00:00:00 至 To 2025-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
课题负责人采用计算机随机方法产生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The person in charge of the project uses computer random method to generate random sequence |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
none |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
拟于2024年12月公开原始数据。公开方式:存放于医院数据管理系统中,需要者可随时向课题负责人索取 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data will be released in December 2024. Public mode: stored in the hospital data management system, and can be obtained from the project leader at any time |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
设计病例记录表,由经过培训的责任护士完成数据的采集和记录;采用由北京大学医学研究所提供的数据采集和管理系统记录和存储数据,并完成数据的自动检查校对。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
A case record form was designed, in which trained nurses were responsible for data collection and recording; the data acquisition and management system provided by Beijing University Medical Research Institute was used to record and store data, and automatic check and proofreading of data was completed. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |